TotalPharma
ActiveSummary
TotalPharma has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €246,119 and a net result of €76,362. Equity is growing by about 39% per year across the filed financial years. Its solvency ranks better than 62% of 20,828 sector peers (NACE 62, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
21-09
NBB filing
Annual accounts filed
financial year 2025 · micro format · 52 days late
2025
31-12
Financial
Equity above €200,000equity €246,119 ▲45%
A profit in every financial year since 2023 builds equity to €246,119.
26-09
NBB filing
Annual accounts filed
financial year 2024 · micro format · 57 days late
2024
31-12
Financial
Weakest financial yearnet €56,701 ▼48.5%
Net result drops to €56,701, the lowest in the series; recovery starts the following year.
31-12
Financial
Liquidity more than doubledcurrent ratio 2.16
Current ratio from 0.93 to 2.16; short-term debt falls from €105,237 to €68,539.
31-12
Financial
Equity above €150,000equity €169,758 ▲50.2%
A profit in every financial year since 2023 builds equity to €169,758.
27-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 27 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.